Originator strategies play role in generic delays, says EGA
This article was originally published in Scrip
Executive Summary
The European Commission's preliminary report on the pharmaceutical sector inquiry is correct to conclude that delays to generic entry represent an important failure of the competitive process, says the European generics industry body, theEGA.